ストックスクリーナーアプリを入手
39.23
0.00%
0.00
アフターアワーズ：
39.23
Ptc Therapeutics Inc (PTCT) 最新ニュース
PTC Therapeutics (NASDAQ:PTCT) Stock Price Down 7.4%Should You Sell? - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com
PTC Therapeutics wins FDA nod for gene therapy - MSN
PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - Citeline News & Insights
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL
AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times
PTC wins US approval of gene therapy for fatal enzyme disorder - BioPharma Dive
PRV sweetens PTC approval of Kebilidi in AADC deficiency - BioWorld Online
FDA nod for AADC deficiency gene therapy from PTC - The Pharma Letter
PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Pharmaceutical Technology
PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace
PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters
PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan
PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Canada
Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Earnings call: PTC Therapeutics raises 2024 revenue outlook - Investing.com
Wellington Management Group LLP's Strategic Reduction in PTC The - GuruFocus.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Re - GuruFocus.com
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Analyst Upgrade - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $48.00 - MarketBeat
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
PTC Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
PTC Therapeutics Reports Strong Q3 2024 Performance - TipRanks
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings: Revenue Surges to $196.8M, Beating Estimates; GAAP EPS at -$1.39 - GuruFocus.com
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Canada Finance
PTC Therapeutics earnings beat by $0.12, revenue topped estimates - Investing.com UK
PTC Therapeutics Raises 2024 Guidance as Q3 Revenue Hits $196.8M, Pipeline Expands | PTCT Stock News - StockTitan
PTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week HighWhat's Next? - MarketBeat
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics - MSN
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
PTC Therapeutics to Participate at Upcoming Investor Conferences - StockTitan
PTC Therapeutics resubmitted NDA for Translarna accepted by FDA - MSN
PTC Therapeutics (PTCT) Scheduled to Post Earnings on Thursday - MarketBeat
FDA Accepts Resubmission of Translarna NDA for Duchenne - Managed Healthcare Executive
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighHere's What Happened - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127% - Yahoo Finance
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission - StockTitan
PTC to ask for FDA approval of vatiquinone for FA by year’s end - Friedreich's Ataxia News
Assenagon Asset Management S.A. Has $18.27 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics sees positive long-term results on vatiquinone for Friedreich ataxia - MSN
PTCTPTC Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighHere's What Happened - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - StockTitan
Objective long/short (PTCT) Report - Stock Traders Daily
PTC Therapeutics (NASDAQ:PTCT) Shares Up 4.5%Should You Buy? - MarketBeat
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):